CGN — Cognetivity Neurosciences Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Annual income statement for Cognetivity Neurosciences, fiscal year end - January 31st, CAD millions except per share, conversion factor applied.
2019 January 31st | 2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0.045 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4.21 | 2.61 | 1.87 | 13 | 6.36 |
| Operating Profit | -4.21 | -2.61 | -1.87 | -13 | -6.31 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -4.19 | -2.66 | -1.93 | -13.1 | -7.43 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.19 | -2.65 | -1.93 | -13.1 | -7.43 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.19 | -2.65 | -1.93 | -13.1 | -7.43 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.19 | -2.65 | -1.93 | -13.1 | -7.43 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.104 | -0.058 | -0.033 | -0.18 | -0.075 |